Drugs / BI 765063
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05446129 | Sep 2022 → Aug 2023 | colorectal cancer | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05249426 | Apr 2022 → Jul 2024 | head and neck squamous cell carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05068102 | Mar 2022 → Jan 2026 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04653142 | Dec 2020 → Apr 2022 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03990233 | Apr 2019 → Apr 2023 | cancer | OSE Immunotherapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249426 ↗ |
| Action | Inhibit | “mAb antagonist to SIRPα receptor” NCT03990233 ↗ |
| Modality | Monoclonal antibody | “a Monoclonal Antibody (mAb) Antagonist” NCT03990233 ↗ |
| Route | Other | “Participants get BI 765063 alone or together with BI 754091 as infusion every 3 weeks.” NCT04653142 ↗ |